<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30199738</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1873-622X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>110</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>29</Day>                    </PubDate>                </JournalIssue>                <Title>Behaviour research and therapy</Title>                <ISOAbbreviation>Behav Res Ther</ISOAbbreviation>            </Journal>            <ArticleTitle>A randomised controlled trial of memory flexibility training (MemFlex) to enhance memory flexibility and reduce depressive symptomatology in individuals with major depressive disorder.</ArticleTitle>            <Pagination>                <MedlinePgn>22-30</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0005-7967(18)30135-9</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.brat.2018.08.008</ELocationID>            <Abstract>                <AbstractText>Successful navigation within the autobiographical memory store is integral to daily cognition. Impairment in the flexibility of memory retrieval can thereby have a detrimental impact on mental health. This randomised controlled phase II exploratory trial (N = 60) evaluated the potential of a novel intervention drawn from basic science - an autobiographical Memory Flexibility (MemFlex) training programme - which sought to ameliorate memory difficulties and improve symptoms of Major Depressive Disorder. MemFlex was compared to Psychoeducation (an evidence-based low-intensity intervention) to determine the likely range of effects on a primary cognitive target of memory flexibility at post-intervention, and co-primary clinical targets of self-reported depressive symptoms and diagnostic status at three-month follow-up. These effect sizes could subsequently be used to estimate sample size for a fully-powered trial. Results demonstrated small-moderate, though as expected statistically non-significant, effect sizes in favour of MemFlex for memory flexibility (d = 0.34, p = .20), and loss of diagnosis (OR = 0.65, p = .48), along with the secondary outcome of depression-free days (d = 0.36, p = .18). A smaller effect size was observed for between-group difference in self-reported depressive symptoms (d = 0.24, p = .35). Effect sizes in favour of MemFlex in this early-stage trial suggest that fully-powered evaluation of MemFlex may be warranted as an avenue to improving low-intensity treatment of depression.</AbstractText>                <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov, Identifier NCT02371291.</AbstractText>                <CopyrightInformation>Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hitchcock</LastName>                    <ForeName>Caitlin</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom; Cambridgeshire and Peterborough NHS Foundation Trust, United Kingdom. Electronic address: Caitlin.hitchcock@mrc-cbu.cam.ac.uk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gormley</LastName>                    <ForeName>Siobhan</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rees</LastName>                    <ForeName>Catrin</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rodrigues</LastName>                    <ForeName>Evangeline</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gillard</LastName>                    <ForeName>Julia</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Panesar</LastName>                    <ForeName>Inderpal</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom; Cambridgeshire and Peterborough NHS Foundation Trust, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wright</LastName>                    <ForeName>Isobel M</ForeName>                    <Initials>IM</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom; Cambridgeshire and Peterborough NHS Foundation Trust, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hammond</LastName>                    <ForeName>Emily</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Watson</LastName>                    <ForeName>Peter</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Werner-Seidler</LastName>                    <ForeName>Aliza</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>The Black Dog Institute, Sydney, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dalgleish</LastName>                    <ForeName>Tim</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom; Cambridgeshire and Peterborough NHS Foundation Trust, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <DataBankList CompleteYN="Y">                <DataBank>                    <DataBankName>ClinicalTrials.gov</DataBankName>                    <AccessionNumberList>                        <AccessionNumber>NCT02371291</AccessionNumber>                    </AccessionNumberList>                </DataBank>            </DataBankList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Behav Res Ther</MedlineTA>            <NlmUniqueID>0372477</NlmUniqueID>            <ISSNLinking>0005-7967</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Autobiographical memory</Keyword>            <Keyword MajorTopicYN="N">Depression</Keyword>            <Keyword MajorTopicYN="N">Low-intensity treatment</Keyword>            <Keyword MajorTopicYN="N">Memory flexibility</Keyword>            <Keyword MajorTopicYN="N">Randomised controlled trial</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30199738</ArticleId>            <ArticleId IdType="pii">S0005-7967(18)30135-9</ArticleId>            <ArticleId IdType="doi">10.1016/j.brat.2018.08.008</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30195173</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1573-2517</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>242</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Jun</Month>                        <Day>27</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of affective disorders</Title>                <ISOAbbreviation>J Affect Disord</ISOAbbreviation>            </Journal>            <ArticleTitle>The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature.</ArticleTitle>            <Pagination>                <MedlinePgn>195-210</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0165-0327(18)31120-0</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2018.06.045</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Major depressive disorder (MDD) is a global public health concern. In particular, treatment-resistant depression (TRD) represents a key unmet need in the management of MDD. A systematic review of the epidemiological and economic literature on the burden associated with an increasing number of treatment steps due to TRD/non-response within an MDD episode was performed to quantify the burden of TRD.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Studies were identified in the PubMed/Medline databases through April 27th, 2017. Articles were limited to full-length peer-reviewed journal publications with no date restrictions. Economic and patient health-related quality of life (HRQoL) data on non-response by the number of treatment steps were quantified and, where appropriate, compared across studies; otherwise, comparative data within studies were reported.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The 12 studies on economic burden found an association between increasing levels of TRD/non-response and elevations in direct and indirect costs. Likewise, the 19 studies studying HRQoL burden found that increasing levels of TRD/non-response correlated with reduced patient HRQoL and health status.</AbstractText>                <AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">TRD is defined inconsistently, which results in notable heterogeneity between published studies and poses methodological challenges for between-study comparisons. It is unknown if the increased economic and patient HRQoL burden are due to factors associated with TRD/non-response in addition to those due to depression persistence or severity.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A consistent trend was observed such that medical costs increased and patient HRQoL and health status decreased by increasing level of TRD/non-response within an MDD episode. These findings highlight the need for improved therapies for TRD to help reduce disease burden.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier B.V. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Johnston</LastName>                    <ForeName>Karissa M</ForeName>                    <Initials>KM</Initials>                    <AffiliationInfo>                        <Affiliation>Broadstreet HEOR, Vancouver, BC, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Powell</LastName>                    <ForeName>Lauren C</ForeName>                    <Initials>LC</Initials>                    <AffiliationInfo>                        <Affiliation>Broadstreet HEOR, Vancouver, BC, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Anderson</LastName>                    <ForeName>Ian M</ForeName>                    <Initials>IM</Initials>                    <AffiliationInfo>                        <Affiliation>The University of Manchester, Manchester, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Szabo</LastName>                    <ForeName>Shelagh</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Broadstreet HEOR, Vancouver, BC, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cline</LastName>                    <ForeName>Stephanie</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Takeda Pharmaceuticals International, Inc, 1 Takeda Pkwy, Deerfield, IL 60015, USA. Electronic address: stephanie.cline@takeda.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>06</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>J Affect Disord</MedlineTA>            <NlmUniqueID>7906073</NlmUniqueID>            <ISSNLinking>0165-0327</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Burden</Keyword>            <Keyword MajorTopicYN="N">Depressive disorder, major</Keyword>            <Keyword MajorTopicYN="N">Review</Keyword>            <Keyword MajorTopicYN="N">Treatment-resistant depression</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30195173</ArticleId>            <ArticleId IdType="pii">S0165-0327(18)31120-0</ArticleId>            <ArticleId IdType="doi">10.1016/j.jad.2018.06.045</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30184551</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1423-033X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>Psychopathology</Title>                <ISOAbbreviation>Psychopathology</ISOAbbreviation>            </Journal>            <ArticleTitle>Cognitive Impairment Along the Course of Depression: Non-Pharmacological Treatment Options.</ArticleTitle>            <Pagination>                <MedlinePgn>1-11</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000492620</ELocationID>            <Abstract>                <AbstractText>Major Depressive Disorder (MDD) is one of the most common psychiatric disorders, with a large global impact on both the individual and the society. In this narrative review, we summarize neurocognitive deficits during acute and (partially) remitted states of depression. Furthermore, we outline the potential negative effect of cognitive impairment (CI) on functional recovery, and discuss the role of several variables in the development of CI for MDD patients. Though there is cumulating evidence regarding persistent CI in unipolar depression, research on treatment options specific for this patient group is still scarce. Hence the central aim of our review is to present non-pharmacological interventions, which are thought to reduce CI in affected MDD patients. We discuss cognitive remediation therapy (CRT), physical exercise, yoga, mindfulness-based therapy, and modern neuromodulation approaches like neurostimulation and neurofeedback training. In conclusion, we propose future directions for research on CI in depression. Looking further ahead, we suggest creative interventional designs that include a direct comparison of different non-pharmacological treatment approaches on neurocognition and functional outcome of MDD. Furthermore, additive and synergistic effects of CRT with other treatment approaches should be examined and compared to create multimodal and even personalized intervention programs.</AbstractText>                <CopyrightInformation>© 2018 S. Karger AG, Basel.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Listunova</LastName>                    <ForeName>Lena</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Adult Psychiatry, Center for Psychosocial Medicine, Division Neurocognition, University of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Roth</LastName>                    <ForeName>Corinna</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Adult Psychiatry, Center for Psychosocial Medicine, Division Neurocognition, University of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bartolovic</LastName>                    <ForeName>Marina</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Adult Psychiatry, Center for Psychosocial Medicine, Division Neurocognition, University of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kienzle</LastName>                    <ForeName>Johanna</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Adult Psychiatry, Center for Psychosocial Medicine, Division Neurocognition, University of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bach</LastName>                    <ForeName>Claudia</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Adult Psychiatry, Center for Psychosocial Medicine, Division Neurocognition, University of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Weisbrod</LastName>                    <ForeName>Matthias</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Adult Psychiatry, Center for Psychosocial Medicine, Division Neurocognition, University of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Adult Psychiatry, SRH-Klinik, Karlsbad-Langensteinbach, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Roesch-Ely</LastName>                    <ForeName>Daniela</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Adult Psychiatry, Center for Psychosocial Medicine, Division Neurocognition, University of Heidelberg, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Psychopathology</MedlineTA>            <NlmUniqueID>8401537</NlmUniqueID>            <ISSNLinking>0254-4962</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cognition disorders</Keyword>            <Keyword MajorTopicYN="N">Cognitive remediation</Keyword>            <Keyword MajorTopicYN="N">Depressive disorder</Keyword>            <Keyword MajorTopicYN="N">Mindfulness-based therapy</Keyword>            <Keyword MajorTopicYN="N">Neuromodulation approach</Keyword>            <Keyword MajorTopicYN="N">Physical exercise</Keyword>            <Keyword MajorTopicYN="N">Review</Keyword>            <Keyword MajorTopicYN="N">Yoga</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30184551</ArticleId>            <ArticleId IdType="pii">000492620</ArticleId>            <ArticleId IdType="doi">10.1159/000492620</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30176845</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>06</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1471-244X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>18</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>03</Day>                    </PubDate>                </JournalIssue>                <Title>BMC psychiatry</Title>                <ISOAbbreviation>BMC Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Self-monitoring and personalized feedback based on the experiencing sampling method as a tool to boost depression treatment: a protocol of a pragmatic randomized controlled trial (ZELF-i).</ArticleTitle>            <Pagination>                <MedlinePgn>276</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12888-018-1847-z</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Depression is a leading cause of disability worldwide. To reduce the societal burden and improve quality of life for individual patients, treatments for depression need to be optimized. There is a particular need for person-tailored interventions that reinforce self-management of patients. Systematic self-monitoring and personalized feedback through the Experience Sampling Method (ESM) could provide such a person-tailored, empowering intervention that enhances treatment outcomes. The primary aim of this study is to investigate the efficacy of self-monitoring and personalized feedback as an add-on tool in the treatment of depressive complaints in a natural setting.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">The ZELF-i study is a pragmatic multi-site randomized controlled trial (RCT). We aim to recruit 150 individuals with depressive symptoms aged between 18 and 65 years, who have an intake for outpatient basic or specialized treatment at a mental health care organization in the North of the Netherlands. After the intake, participants will be randomly allocated to one of three study arms: two experimental groups engaging in 28 days of systematic self-monitoring (5 times per day) and receiving weekly personalized feedback on positive affect and activities (&quot;Do&quot;-module) or on negative affect and thinking patterns (&quot;Think&quot;-module), and a control group receiving no additional intervention. Self-report inventories of depressive symptoms, psychosocial functioning and feelings of empowerment will be administered before and after the intervention period, and at follow-up measurements at 1, 2, 3 and 6 months. The patient-experienced utility of the intervention will be investigated by a combination of quantitative and qualitative research methods.</AbstractText>                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The present study is the first to examine the effects of add-on self-monitoring and personalized feedback on depressive complaints in clinical practice. It is also the first to evaluate two different ESM modules targeted at both of depression's core symptoms. Lastly, it is the first study that uses a combination of qualitative and quantitative methods to evaluate the patient-experienced utility of ESM with personalized feedback as an intervention for depression. Results of the present study may improve treatment for depression, if the intervention is found to be effective.</AbstractText>                <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Dutch Trial Register, NTR5707 , registered prospectively 1 February 2016.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Bastiaansen</LastName>                    <ForeName>Jojanneke A</ForeName>                    <Initials>JA</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4831-6402</Identifier>                    <AffiliationInfo>                        <Affiliation>University of Groningen, University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion Regulation, Groningen, The Netherlands. j.bastiaansen@umcg.nl.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Friesland Mental Health Care Services, Department of Education and Research, Leeuwarden, The Netherlands. j.bastiaansen@umcg.nl.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Meurs</LastName>                    <ForeName>Maaike</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>University of Groningen, University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion Regulation, Groningen, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stelwagen</LastName>                    <ForeName>Renee</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Friesland Mental Health Care Services, Department of Education and Research, Leeuwarden, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wunderink</LastName>                    <ForeName>Lex</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Friesland Mental Health Care Services, Department of Education and Research, Leeuwarden, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schoevers</LastName>                    <ForeName>Robert A</ForeName>                    <Initials>RA</Initials>                    <AffiliationInfo>                        <Affiliation>University of Groningen, University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion Regulation, Groningen, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wichers</LastName>                    <ForeName>Marieke</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>University of Groningen, University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion Regulation, Groningen, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Oldehinkel</LastName>                    <ForeName>Albertine J</ForeName>                    <Initials>AJ</Initials>                    <AffiliationInfo>                        <Affiliation>University of Groningen, University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion Regulation, Groningen, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>2015-05</GrantID>                    <Agency>Gratama Stichting</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>239</GrantID>                    <Agency>Stichting tot Steun Vereniging tot Christelijke Verzorging van Geestes- en Zenuwzieken</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMC Psychiatry</MedlineTA>            <NlmUniqueID>100968559</NlmUniqueID>            <ISSNLinking>1471-244X</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Ned Tijdschr Geneeskd. 2004 Oct 16;148(42):2057-9</RefSource>                <PMID Version="1">15532326</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Psychiatry. 2015 Jul 24;15:172</RefSource>                <PMID Version="1">26205099</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2012 Jun;42(6):1119-29</RefSource>                <PMID Version="1">22008511</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2011 Jul 26;343:d4163</RefSource>                <PMID Version="1">21791490</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JMIR Ment Health. 2014 Dec 23;1(1):e5</RefSource>                <PMID Version="1">26543905</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychosom Res. 1994 Jan;38(1):33-40</RefSource>                <PMID Version="1">8126688</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2000 Jan 8;320(7227):114-6</RefSource>                <PMID Version="1">10625273</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World Psychiatry. 2014 Feb;13(1):68-77</RefSource>                <PMID Version="1">24497255</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neuropsychiatry Clin Neurosci. 2015 Summer;27(3):179-87</RefSource>                <PMID Version="1">25658681</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World Psychiatry. 2013 Jun;12(2):113-7</RefSource>                <PMID Version="1">23737412</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Psychiatr Scand Suppl. 2003;(416):24-9</RefSource>                <PMID Version="1">12755851</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 2013 Sep;170(9):1041-50</RefSource>                <PMID Version="1">24030613</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Opin Psychiatry. 2016 Jul;29(4):258-63</RefSource>                <PMID Version="1">27153125</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychosom Res. 2014 Jul;77(1):34-9</RefSource>                <PMID Version="1">24913339</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychosom Res. 1994 Jan;38(1):23-32</RefSource>                <PMID Version="1">8126686</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2014 Mar 07;348:g1687</RefSource>                <PMID Version="1">24609605</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Ment Health. 2010 Aug;19(4):352-62</RefSource>                <PMID Version="1">20636115</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Psychiatry. 2015 Nov;30(8):900-6</RefSource>                <PMID Version="1">26647864</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Psychol Rev. 2012 Aug;32(6):510-23</RefSource>                <PMID Version="1">22721999</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ned Tijdschr Geneeskd. 2012;156(19):A4337</RefSource>                <PMID Version="1">22571545</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychosom Res. 2001 Dec;51(6):729-33</RefSource>                <PMID Version="1">11750295</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2003 Sep 1;54(5):573-83</RefSource>                <PMID Version="1">12946886</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2009 Sep;39(9):1533-47</RefSource>                <PMID Version="1">19215626</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ Case Rep. 2012 Jun 08;2012:null</RefSource>                <PMID Version="1">22684840</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Health Psychol. 2016 May;35(5):433-41</RefSource>                <PMID Version="1">26690641</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 1996 May;26(3):477-86</RefSource>                <PMID Version="1">8733206</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JMIR Res Protoc. 2015 Aug 07;4(3):e100</RefSource>                <PMID Version="1">26254160</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Internet Res. 2012 Jun 25;14(3):e67</RefSource>                <PMID Version="1">22732135</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Environ Res Public Health. 2014 Oct 21;11(10):10915-39</RefSource>                <PMID Version="1">25337940</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychosom Med. 2012 May;74(4):377-86</RefSource>                <PMID Version="1">22582335</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Res Ther. 2002 Jan;40(1):105-20</RefSource>                <PMID Version="1">11762423</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Res Methods. 2007 May;39(2):175-91</RefSource>                <PMID Version="1">17695343</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Psychiatry. 2017 Dec 29;17(1):415</RefSource>                <PMID Version="1">29284448</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Psychiatry. 2015 Oct 14;15:250</RefSource>                <PMID Version="1">26467210</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Depression</Keyword>            <Keyword MajorTopicYN="N">E-health</Keyword>            <Keyword MajorTopicYN="N">Experience sampling</Keyword>            <Keyword MajorTopicYN="N">Intervention</Keyword>            <Keyword MajorTopicYN="N">Personalized medicine</Keyword>            <Keyword MajorTopicYN="N">Randomized Controlled trial</Keyword>            <Keyword MajorTopicYN="N">Self-monitoring</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30176845</ArticleId>            <ArticleId IdType="doi">10.1186/s12888-018-1847-z</ArticleId>            <ArticleId IdType="pii">10.1186/s12888-018-1847-z</ArticleId>            <ArticleId IdType="pmc">PMC6122175</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30176494</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1573-2517</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>242</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>25</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of affective disorders</Title>                <ISOAbbreviation>J Affect Disord</ISOAbbreviation>            </Journal>            <ArticleTitle>Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?</ArticleTitle>            <Pagination>                <MedlinePgn>150-158</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0165-0327(18)30420-8</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2018.08.053</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognitive therapy (CT) improves symptoms in adults with major depressive disorder (MDD) plus comorbid anxiety disorder, but the specific type of anxiety may influence outcomes. This study compared CT outcomes among adults with MDD plus social, other, or no comorbid anxiety disorders.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Outpatients with recurrent MDD (N = 523, including 87 with social and 110 with other comorbid anxiety disorders) received acute-phase CT. Higher risk responders (n = 241 with partial or unstable response) were randomized to 8 months of continuation treatment (CT or clinical management plus fluoxetine or pill placebo), followed by 24 months of assessment. Lower risk responders (n = 49) were assessed for 32 months without additional research treatment. Depression, anxiety symptoms, and social avoidance were measured repeatedly.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Other (non-social), but not social, anxiety disorders predicted elevated depression and anxiety symptoms throughout and after acute-phase CT. Social, but not other, anxiety disorder predicted greater reduction in depressive symptoms during acute-phase CT and elevated social avoidance during and after acute-phase CT.</AbstractText>                <AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Anxiety disorders were assessed only before acute-phase treatment. The anxiety symptom measure was brief. Generalization to other patient populations and treatments is unknown.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Non-social comorbid anxiety disorders may reduce the efficacy of acute-phase CT for MDD by diminishing both short- and longer term outcomes relative to depressed patients without comorbid anxiety disorders. Comorbid social anxiety disorder may increase relative reductions in depressive symptoms during acute-phase CT for MDD, but patients with comorbid social anxiety disorder may require specialized focus on social avoidance during CT.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier B.V.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Vittengl</LastName>                    <ForeName>Jeffrey R</ForeName>                    <Initials>JR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, Truman State University, Kirksville, MO, USA. Electronic address: vittengl@truman.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Clark</LastName>                    <ForeName>Lee Anna</ForeName>                    <Initials>LA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Notre Dame, Notre Dame, IN, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Smits</LastName>                    <ForeName>Jasper A J</ForeName>                    <Initials>JAJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Texas at Austin, Asutin, TX, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thase</LastName>                    <ForeName>Michael E</ForeName>                    <Initials>ME</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jarrett</LastName>                    <ForeName>Robin B</ForeName>                    <Initials>RB</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: Robin.Jarrett@UTSouthwestern.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>J Affect Disord</MedlineTA>            <NlmUniqueID>7906073</NlmUniqueID>            <ISSNLinking>0165-0327</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Anxiety disorders</Keyword>            <Keyword MajorTopicYN="N">Cognitive therapy</Keyword>            <Keyword MajorTopicYN="N">Comorbidity</Keyword>            <Keyword MajorTopicYN="N">Fluoxetine</Keyword>            <Keyword MajorTopicYN="N">Major depressive disorder</Keyword>            <Keyword MajorTopicYN="N">Social anxiety disorder</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30176494</ArticleId>            <ArticleId IdType="pii">S0165-0327(18)30420-8</ArticleId>            <ArticleId IdType="doi">10.1016/j.jad.2018.08.053</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30156122</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>29</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1477-0334</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>29</Day>                    </PubDate>                </JournalIssue>                <Title>Statistical methods in medical research</Title>                <ISOAbbreviation>Stat Methods Med Res</ISOAbbreviation>            </Journal>            <ArticleTitle>Asymptotic and exact interval estimators of the common odds ratio under the sequential parallel comparison design.</ArticleTitle>            <Pagination>                <MedlinePgn>962280218796255</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/0962280218796255</ELocationID>            <Abstract>                <AbstractText>When studying treatments for psychiatric or mental diseases in a placebo-controlled trial, we may consider use of the sequential parallel comparison design to reduce the number of patients needed through the reduction of the high placebo response rate. Under the assumption that the odds ratio of responses is constant between phases in the sequential parallel comparison design, we derive the conditional maximum likelihood estimator for the odds ratio. On the basis of the conditional likelihood, we further derive three asymptotic interval and an exact interval estimators for the odds ratio of responses. We employ Monte Carlo simulation to evaluate the performance of these interval estimators in a variety of situations. We find that the asymptotic interval and exact interval estimators developed here can all perform well. We use the double-blind, placebo-controlled study assessing the efficacy of a low dose of aripiprazole adjunctive to antidepressant therapy for treating patients with major depressive disorder to illustrate the use of these estimators.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lui</LastName>                    <ForeName>Kung-Jong</ForeName>                    <Initials>KJ</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0002-5413-2514</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Mathematics and Statistics, San Diego State University, San Diego, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Stat Methods Med Res</MedlineTA>            <NlmUniqueID>9212457</NlmUniqueID>            <ISSNLinking>0962-2802</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Exact interval estimator</Keyword>            <Keyword MajorTopicYN="N">Mantel–Haenszel estimator</Keyword>            <Keyword MajorTopicYN="N">conditional likelihood</Keyword>            <Keyword MajorTopicYN="N">coverage probability</Keyword>            <Keyword MajorTopicYN="N">sequential parallel comparison design</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30156122</ArticleId>            <ArticleId IdType="doi">10.1177/0962280218796255</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30155392</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>31</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">2168-9709</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>8</Volume>                    <Issue>4</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                    </PubDate>                </JournalIssue>                <Title>The mental health clinician</Title>                <ISOAbbreviation>Ment Health Clin</ISOAbbreviation>            </Journal>            <ArticleTitle>Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?</ArticleTitle>            <Pagination>                <MedlinePgn>175-183</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.9740/mhc.2018.07.175</ELocationID>            <Abstract>                <AbstractText Label="Introduction" NlmCategory="UNASSIGNED">Past trials of buprenorphine (BUP) in the treatment of major depressive disorder (MDD) have displayed favorable results, although its clinical utility was limited by the risk of abuse or physical dependence. By combining BUP with samidorphan (SAM), the euphoric high is negated by an opposing mechanism, which theoretically reduces addictive-like properties while allowing the antidepressant properties to remain. As such, the objective of this article is to analyze the results of BUP/SAM premarketing clinical trials as adjunctive treatment for treatment-resistant MDD.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">A comprehensive PubMed/MEDLINE search was conducted through November 9, 2017, using the following search terms: depression, samidorphan, buprenorphine, ALKS-5461. Additional data were obtained from Clinicaltrials.gov and resources included in the present study. All English-language clinical trials evaluating the combination of BUP/SAM in the treatment of MDD were included.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">A few premarketing studies have evaluated the efficacy and safety of BUP/SAM combination as adjunctive treatment in patients with treatment-resistant MDD. The FORWARD-1 through FORWARD-5 trials concluded (1) the most effective dosing ratio of BUP/SAM to reduce abuse potential was 1:1; (2) statistically significant changes in scores from baseline on the Montgomery-Asberg Depression Rating Scale were noted for the 2 mg/2 mg dose compared with placebo; and (3) the most commonly reported adverse effects were nausea, dizziness, and fatigue.</AbstractText>                <AbstractText Label="Discussion" NlmCategory="UNASSIGNED">Buprenorphine/samidorphan has shown favorable results for efficacy and tolerability in premarketing studies evaluating its use as adjunctive therapy for treatment-resistant MDD. Its novel mechanism targeting the opioid pathway may serve as a promising antidepressant devoid of abuse potential.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Peckham</LastName>                    <ForeName>Alyssa M</ForeName>                    <Initials>AM</Initials>                    <Identifier Source="ORCID">0000-0002-9638-7005</Identifier>                    <AffiliationInfo>                        <Affiliation>(Corresponding author) Clinical Assistant Professor, Northeastern University, Bouve College of Health Sciences, School of Pharmacy; Clinical Addiction Pharmacist, Massachusetts General Hospital, Boston, Massachusetts, a.peckham@northeastern.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>De La Cruz</LastName>                    <ForeName>Austin</ForeName>                    <Initials>A</Initials>                    <Identifier Source="ORCID">0000-0002-6807-4474</Identifier>                    <AffiliationInfo>                        <Affiliation>Clinical Assistant Professor, Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dufresne</LastName>                    <ForeName>Robert L</ForeName>                    <Initials>RL</Initials>                    <Identifier Source="ORCID">0000-0003-0479-3813</Identifier>                    <AffiliationInfo>                        <Affiliation>Professor of Pharmacy and INBRE Behavioral Science Coordinator, Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston, Rhode Island.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>06</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Ment Health Clin</MedlineTA>            <NlmUniqueID>101728585</NlmUniqueID>            <ISSNLinking>2168-9709</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 2006 Jan;163(1):28-40</RefSource>                <PMID Version="1">16390886</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychopharmacol. 1995 Feb;15(1):49-57</RefSource>                <PMID Version="1">7714228</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2014 May 09;9(5):e97216</RefSource>                <PMID Version="1">24816773</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2011 Jan;36(1):369-70</RefSource>                <PMID Version="1">21116263</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2003 Apr 15;53(8):649-59</RefSource>                <PMID Version="1">12706951</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychoneuroendocrinology. 2015 Dec;62:389-91</RefSource>                <PMID Version="1">26386543</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Neurosci. 2006 Feb;7(2):137-51</RefSource>                <PMID Version="1">16429123</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Subst Abuse Treat. 1990;7(1):51-4</RefSource>                <PMID Version="1">2313769</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 2006 Nov;163(11):1905-17</RefSource>                <PMID Version="1">17074942</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychiatry. 2014 Aug;75(8):e785-93</RefSource>                <PMID Version="1">25191915</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>AAPS J. 2009 Jun;11(2):312-22</RefSource>                <PMID Version="1">19430912</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Subst Abuse Treat. 2002 Sep;23(2):87-92</RefSource>                <PMID Version="1">12220606</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychopharmacol. 2015 Jun;35(3):242-9</RefSource>                <PMID Version="1">25928699</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychopharmacol. 2008 Oct;28(5):593-5</RefSource>                <PMID Version="1">18794671</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Transl Perioper Pain Med. 2016;1(2):4-16</RefSource>                <PMID Version="1">27213169</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychopharmacology (Berl). 2015 Mar;232(5):907-15</RefSource>                <PMID Version="1">25178815</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pharmacol Exp Ther. 2003 Apr;305(1):323-30</RefSource>                <PMID Version="1">12649385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychopharmacology (Berl). 2005 Nov;183(1):118-26</RefSource>                <PMID Version="1">16184376</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuron. 2002 Mar 28;34(1):13-25</RefSource>                <PMID Version="1">11931738</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2013 Dec;38(13):2623-31</RefSource>                <PMID Version="1">23921954</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychiatry. 1999;60 Suppl 4:4-11; discussion 12-3</RefSource>                <PMID Version="1">10086478</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Vis Exp. 2012 Jan 29;(59):e3638</RefSource>                <PMID Version="1">22314943</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Opin Pharmacother. 2014 Dec;15(17):2525-42</RefSource>                <PMID Version="1">25224953</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Ther. 2015 Feb 1;37(2):338-48</RefSource>                <PMID Version="1">25456560</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Addict Dis. 2008;27(3):49-65</RefSource>                <PMID Version="1">18956529</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2015 May;40(6):1448-55</RefSource>                <PMID Version="1">25518754</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 2016 May 1;173(5):499-508</RefSource>                <PMID Version="1">26869247</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">buprenorphine</Keyword>            <Keyword MajorTopicYN="N">depression</Keyword>            <Keyword MajorTopicYN="N">opioid receptor antagonist</Keyword>            <Keyword MajorTopicYN="N">samidorphan</Keyword>        </KeywordList>        <CoiStatement>Disclosures: The authors have nothing to disclose.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30155392</ArticleId>            <ArticleId IdType="doi">10.9740/mhc.2018.07.175</ArticleId>            <ArticleId IdType="pmc">PMC6063454</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30152283</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>28</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1875-6190</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>27</Day>                    </PubDate>                </JournalIssue>                <Title>Current neuropharmacology</Title>                <ISOAbbreviation>Curr Neuropharmacol</ISOAbbreviation>            </Journal>            <ArticleTitle>Psychopharmacotherapy of obsessive-compulsive symptoms within the framework of Tourette syndrome.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.2174/1570159X16666180828095131</ELocationID>            <Abstract>                <AbstractText>While Behavioral Therapy (BT) should be recommended as the first step in the treatment of OCD as well as TS, medication can be added for augmentation and in certain situations (e.g. family preference, BT not available or feasible) the priority may even reverse. This narrative review is given on the complexity of drug treatment in patients comorbid for obsessive-compulsive disorder (OCD) and Tourette syndrome (TS) and other tic problems. OCD with TS is a co-occuring combination of two generally delimitable, but in detail also overlapping disorders which wax and wane with time but have different courses and necessities and options of treatment. Distinct subtypes like &quot;tic-related OCD&quot; are questionable. Obsessive-compulsive symptoms (OCS) and tics are frequently associated (OCS in TS up to 90%, tics in OCD up to 37%). Sensory-motor phenomena like urges and just-right feelings reflect some behavioral overlap. The main additional psychopathologies are attention-deficit hyperactivity disorder (ADHD), mood problems and anxiety. Also, hair pulling disorder and skin picking disorder are related to OCD with TS. Hence, the assessment and drug treatment of its many psychopathological problems needs high clinical experience, careful planning, and ongoing evaluation/adaptation. Drugs are able to reduce clinical symptoms but cannot cure the disorders, which should be treated in parallel in their own right; i.e. for OCD serotonin reuptake inhibitors (SSRI) and for TS (tics) certain antipsychotics can be successfully prescribed. In cases of OCD with tics, when OCS respond only partially, an augmentation with antipsychotics (recommended: aripiprazole and risperidone) may improve OCS as well as tics. Also, the benzamide sulpiride, an atypical antipsychotics, may be beneficial in treating the combination of OCS, tics and anxious-depressive problems. Probably, any additional psychopathologies of OCD might attenuate the effectiveness of SSRI on OCS; on the other hand, in cases of OCD with tics, SSRI may reduce not only OCS but also stress sensitivity and emotional problems and thus leading to better selfregulatory abilities, useful to improve tic suppression. In sum, some clinical guidance can be given, but there remain many uncertainties because of a scarce data base for psychopharmacotherapy in OCD with TS.   Recently, a high quality primer on Tourette Syndrome (TS) has been published, giving a timely and comprehensive overview related to all relevant aspects of the disorder [1]. This includes the suggestion that primarily Behavior Therapy (BT) should be recommended for the treatment of both OCS/OCD and TS. BT seems to be equally effective for pure as well as tic-related OCD [2-4]. But many patients remain symptomatic after BT intervention. In this situation, medication comes into play for augmentation. Further, drug treatment may be given the priority if BT is not available, not feasible or not preferred by the family. Concerning the practically important relationship between obsessive-compulsive symptoms (OCS) and TS the present review will broaden this issue while starting with the essentials on core aspects of TS before presenting obsessive-compulsive symptoms/disorder (OCS/OCD) as comorbidities with TS. Several levels of investigation are mentioned (e.g. psychopathology, pathophysiology, psychosocial burden) and their specific meanings for psychopharmacological treatment are discussed. Finally, certain drugs are explored for their use in treatment of OCS/OCD within the framework of TS.</AbstractText>                <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rothenberger</LastName>                    <ForeName>Aribert</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Clinic for Child and Adolescent Psychiatry and Psychotherapy University Medical Center Göttingen. Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Roessner</LastName>                    <ForeName>Veit</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Child and Adolescent Psychiatry and Psychotherapy TU Dresden. Germany.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United Arab Emirates</Country>            <MedlineTA>Curr Neuropharmacol</MedlineTA>            <NlmUniqueID>101157239</NlmUniqueID>            <ISSNLinking>1570-159X</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">SSRI</Keyword>            <Keyword MajorTopicYN="N">associated psychopathology</Keyword>            <Keyword MajorTopicYN="N">comorbidity</Keyword>            <Keyword MajorTopicYN="N">drug treatment</Keyword>            <Keyword MajorTopicYN="N">neuroleptics</Keyword>            <Keyword MajorTopicYN="N">obsessive-compulsive symptoms </Keyword>            <Keyword MajorTopicYN="N">tic disorders</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30152283</ArticleId>            <ArticleId IdType="pii">CN-EPUB-92617</ArticleId>            <ArticleId IdType="doi">10.2174/1570159X16666180828095131</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30138433</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>31</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1932-6203</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>13</Volume>                    <Issue>8</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>PloS one</Title>                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>            </Journal>            <ArticleTitle>Effect of collaborative depression treatment on risk for diabetes: A 9-year follow-up of the IMPACT randomized controlled trial.</ArticleTitle>            <Pagination>                <MedlinePgn>e0200248</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0200248</ELocationID>            <Abstract>                <AbstractText>Considerable epidemiologic evidence and plausible biobehavioral mechanisms suggest that depression is an independent risk factor for diabetes. Moreover, reducing the elevated diabetes risk of depressed individuals is imperative given that both conditions are leading causes of death and disability. However, because no prior study has examined clinical diabetes outcomes among depressed patients at risk for diabetes, the question of whether depression treatment prevents or delays diabetes onset remains unanswered. Accordingly, we examined the effect of a 12-month collaborative care program for late-life depression on 9-year diabetes incidence among depressed, older adults initially free of diabetes. Participants were 119 primary care patients [M (SD) age: 67.2 (6.9) years, 41% African American] with a depressive disorder but without diabetes enrolled at the Indiana sites of the Improving Mood-Promoting Access to Collaborative Treatment (IMPACT) trial. Incident diabetes cases were defined as diabetes diagnoses, positive laboratory values, or diabetes medication prescription, and were identified using electronic medical record and Medicare/Medicaid data. Surprisingly, the rate of incident diabetes in the collaborative care group was 37% (22/59) versus 28% (17/60) in the usual care group. Even though the collaborative care group exhibited greater reductions in depressive symptom severity (p = .024), unadjusted (HR = 1.29, 95% CI: 0.69-2.43, p = .428) and adjusted (HR = 1.18, 95% CI: 0.61-2.29, p = .616) Cox proportional hazards models indicated that the risk of incident diabetes did not differ between the treatment groups. Our novel preliminary findings raise the possibility that depression treatment alone may be insufficient to reduce the excess diabetes risk of depressed, older adults.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Khambaty</LastName>                    <ForeName>Tasneem</ForeName>                    <Initials>T</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0504-0805</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Maryland, Baltimore County, Baltimore, Maryland, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Callahan</LastName>                    <ForeName>Christopher M</ForeName>                    <Initials>CM</Initials>                    <AffiliationInfo>                        <Affiliation>Indiana University Center for Aging Research and Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Regenstrief Institute, Inc., Indianapolis, Indiana, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stewart</LastName>                    <ForeName>Jesse C</ForeName>                    <Initials>JC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, Indiana University-Purdue University Indianapolis, Indianapolis, Indiana, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>PLoS One</MedlineTA>            <NlmUniqueID>101285081</NlmUniqueID>            <ISSNLinking>1932-6203</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2007 Apr;99(1-3):139-45</RefSource>                <PMID Version="1">17049999</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Gen Intern Med. 2001 Sep;16(9):606-13</RefSource>                <PMID Version="1">11556941</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Endocrinol Metab. 2015 Feb;100(2):363-70</RefSource>                <PMID Version="1">25590213</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Psychiatry Med. 2004;34(1):37-50</RefSource>                <PMID Version="1">15242140</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Endocrinol. 2005 Sep;21(3):129-37</RefSource>                <PMID Version="1">16335904</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychiatry. 2010 Oct;71(10):1259-72</RefSource>                <PMID Version="1">21062615</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 2004 Oct;61(10):1042-9</RefSource>                <PMID Version="1">15466678</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Perspect Clin Res. 2011 Oct;2(4):145-8</RefSource>                <PMID Version="1">22145125</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>MD Comput. 1992 Jul-Aug;9(4):206-17</RefSource>                <PMID Version="1">1508033</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 1974 Oct;131(10):1121-3</RefSource>                <PMID Version="1">4416585</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes Metab Res Rev. 2013 May;29(4):273-84</RefSource>                <PMID Version="1">23390036</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2002 Dec 11;288(22):2836-45</RefSource>                <PMID Version="1">12472325</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Bull. 1992 Jul;112(1):155-9</RefSource>                <PMID Version="1">19565683</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes Care. 2013 Apr;36(4):1033-46</RefSource>                <PMID Version="1">23468086</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gen Hosp Psychiatry. 2010 May-Jun;32(3):334-6</RefSource>                <PMID Version="1">20430240</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychopharmacol Bull. 1973 Jan;9(1):13-28</RefSource>                <PMID Version="1">4682398</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Care. 2002 Sep;40(9):771-81</RefSource>                <PMID Version="1">12218768</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes Care. 2010 Jan;33 Suppl 1:S62-9</RefSource>                <PMID Version="1">20042775</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes Care. 2008 Mar;31(3):420-6</RefSource>                <PMID Version="1">18071002</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes Care. 2008 Dec;31(12):2383-90</RefSource>                <PMID Version="1">19033418</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychiatry. 2006 Dec;67(12):1856-61</RefSource>                <PMID Version="1">17194262</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 1994 Dec 14;272(22):1749-56</RefSource>                <PMID Version="1">7966923</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Geriatr Soc. 2013 Nov;61(11):2020-6</RefSource>                <PMID Version="1">24219204</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Metabolism. 2000 Oct;49(10):1255-60</RefSource>                <PMID Version="1">11079812</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 1995 Apr 5;273(13):1026-31</RefSource>                <PMID Version="1">7897786</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes Care. 2010 Dec;33(12):2549-51</RefSource>                <PMID Version="1">20805256</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 1999 Dec;56(12):1109-15</RefSource>                <PMID Version="1">10591288</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychopharmacol. 2008 Oct;28(5):581-4</RefSource>                <PMID Version="1">18794665</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Care. 2001 Aug;39(8):785-99</RefSource>                <PMID Version="1">11468498</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2000 Sep 27;284(12):1519-26</RefSource>                <PMID Version="1">11000645</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>09</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30138433</ArticleId>            <ArticleId IdType="doi">10.1371/journal.pone.0200248</ArticleId>            <ArticleId IdType="pii">PONE-D-17-32162</ArticleId>            <ArticleId IdType="pmc">PMC6107131</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30135780</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>26</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">2214-7829</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>12</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Jun</Month>                    </PubDate>                </JournalIssue>                <Title>Internet interventions</Title>                <ISOAbbreviation>Internet Interv</ISOAbbreviation>            </Journal>            <ArticleTitle>Patient's experience with blended video- and internet based cognitive behavioural therapy service in routine care.</ArticleTitle>            <Pagination>                <MedlinePgn>165-175</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.invent.2018.01.003</ELocationID>            <Abstract>                <AbstractText Label="Introduction" NlmCategory="UNASSIGNED">Internet-based guided self-help and face-to-face CBT have shown to be effective in the treatment of depression, but both approaches might not be an available treatment option for all patients. A treatment which blends internet-based guided self-help with video-based psychotherapy might reduce potential disadvantages of both approaches, while maintaining major advantages such as being location-independent. Additionally, it could provide a stronger focus on patient empowerment and lower resource use compared to traditional face-to-face treatment.</AbstractText>                <AbstractText Label="Aim" NlmCategory="UNASSIGNED">The aim of this study is to evaluate patient's experiences with blended internet- and video-based CBT (blended iCBT) treatment and to derive suggestions for the improvement of such services.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">Semi-structured interviews were conducted with 15 participants of the blended iCBT treatment as part of the European MasterMind trial. Participants included adults suffering from Major Depressive Disorder. The interview guide assessed patient's experiences regarding the four treatment components program, 1. face-to-face diagnostic interviews, 2. video-based synchronous therapy sessions (VTS), 3. online self-help treatment modules (OTM) as well as 4. behaviour diaries and symptom monitoring. Interviews were analyzed using the framework method and outcomes regarding connections within and between participants and categories were generated by counting the statements within relevant themes.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Overall, patients indicated to have been satisfied with all components of the treatment, highlighting the option to independently work from home in their own pace. While the OTMs allowed for a deeper reflection of the content, the VTS with the therapist were mentioned to provide the personal character of the service. The working alliance with the therapist was experienced as fostering the individual fit of the treatment. Patients reported a high self-perceived treatment effectiveness. Negative effects included that some patients felt overwhelmed by the service, e.g. by working with the content of the OTM as they forced them to address their problems. Within the combination of OTM and VTS, both components were rated as equally important and patients felt that the combination depicted a treatment at least equal to regular face-to-face treatment regarding the perceived effectiveness. Other identified themes included patient's individual factors, reactions in their social environment and suggestions for improvement of the service.</AbstractText>                <AbstractText Label="Discussion" NlmCategory="UNASSIGNED">Predominantly, patients reported positive experiences with the blended iCBT service and rate the treatment as adequate and effective to treat their condition. The importance of the VTS is highlighted. Following this approach might be an option to make affordable and effective evidence-based CBT available independent from regional barriers.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Etzelmueller</LastName>                    <ForeName>Anne</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Psychology and Psychotherapy, Friedrich-Alexander University Erlangen Nuremberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Radkovsky</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>University of Marburg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hannig</LastName>                    <ForeName>Wiebke</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>University of Marburg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Berking</LastName>                    <ForeName>Matthias</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Psychology and Psychotherapy, Friedrich-Alexander University Erlangen Nuremberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ebert</LastName>                    <ForeName>David Daniel</ForeName>                    <Initials>DD</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Psychology and Psychotherapy, Friedrich-Alexander University Erlangen Nuremberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>02</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Internet Interv</MedlineTA>            <NlmUniqueID>101631612</NlmUniqueID>            <ISSNLinking>2214-7829</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2002 Oct 5;325(7367):766-70</RefSource>                <PMID Version="1">12364308</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rehabilitation (Stuttg). 2013 Jun;52(3):164-72</RefSource>                <PMID Version="1">23761205</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychother Psychosom. 2015;84(6):348-58</RefSource>                <PMID Version="1">26398885</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2015 May 1;176:9-17</RefSource>                <PMID Version="1">25682378</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Psychiatry. 2013 Nov 26;13:318</RefSource>                <PMID Version="1">24279841</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Internet Res. 2013 Jun 27;15(6):e121</RefSource>                <PMID Version="1">23807565</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 2005 Sep;62(9):1007-14</RefSource>                <PMID Version="1">16143732</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Technol Assess Health Care. 2012 Jan;28(1):44-51</RefSource>                <PMID Version="1">22617736</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trials. 2014 Jan 30;15:39</RefSource>                <PMID Version="1">24476555</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JMIR Ment Health. 2017 Feb 23;4(1):e8</RefSource>                <PMID Version="1">28232298</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Rev Neurother. 2016;16(1):55-60</RefSource>                <PMID Version="1">26610160</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 1999 Nov 10;282(18):1737-44</RefSource>                <PMID Version="1">10568646</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Internet Res. 2012 Jun 26;14(3):e65</RefSource>                <PMID Version="1">22732098</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Psychol (New York). 2008;15(3):243-253</RefSource>                <PMID Version="1">21369344</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Med Res Methodol. 2013 Sep 18;13:117</RefSource>                <PMID Version="1">24047204</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Internet Res. 2016 Aug 31;18(8):e234</RefSource>                <PMID Version="1">27582341</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2009 Aug;116(3):227-31</RefSource>                <PMID Version="1">19167094</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2010 Oct 13;5(10):e13196</RefSource>                <PMID Version="1">20967242</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 2013 Mar;170(3):256-62</RefSource>                <PMID Version="1">23450286</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabet Med. 2017 Jan;34(1):99-107</RefSource>                <PMID Version="1">27334444</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Ther. 2018 Jan;49(1):71-83</RefSource>                <PMID Version="1">29405923</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Psychiatry. 2007 Sep;191:206-11</RefSource>                <PMID Version="1">17766759</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gen Hosp Psychiatry. 2013 Jul-Aug;35(4):332-8</RefSource>                <PMID Version="1">23664503</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Psychiatr Scand. 2011 Oct;124(4):285-94</RefSource>                <PMID Version="1">21401534</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sleep Med Rev. 2016 Dec;30:1-10</RefSource>                <PMID Version="1">26615572</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Psychiatry. 2017 Aug 10;8:116</RefSource>                <PMID Version="1">28848454</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2007 Sep 8;370(9590):841-50</RefSource>                <PMID Version="1">17826169</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trials. 2016 Aug 03;17(1):387</RefSource>                <PMID Version="1">27488181</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ Open. 2017 Dec 28;7(12):e015226</RefSource>                <PMID Version="1">29288172</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cogn Behav Ther. 2009;38 Suppl 1:55-60</RefSource>                <PMID Version="1">19675956</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Psychol Rev. 2012 Jun;32(4):329-42</RefSource>                <PMID Version="1">22466510</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79</RefSource>                <PMID Version="1">21896369</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cochrane Database Syst Rev. 2015 Mar 05;(3):CD011565</RefSource>                <PMID Version="1">25742186</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2017 Dec 1;223:28-40</RefSource>                <PMID Version="1">28715726</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Psychol (New York). 2009 Sep 1;16(3):323-338</RefSource>                <PMID Version="1">20161010</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Depress Anxiety. 2013 Nov;30(11):1058-67</RefSource>                <PMID Version="1">23922191</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Internet Res. 2010 Jun 24;12(2):e23</RefSource>                <PMID Version="1">20581001</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Internet Res. 2017 Jan 04;19(1):e5</RefSource>                <PMID Version="1">28052841</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Res Ther. 2010 Sep;48(9):890-9</RefSource>                <PMID Version="1">20561606</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2016 May 3;315(17):1854-63</RefSource>                <PMID Version="1">27139058</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Internet Res. 2017 Sep 15;19(9):e306</RefSource>                <PMID Version="1">28916506</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2003 Sep 1;54(5):573-83</RefSource>                <PMID Version="1">12946886</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Internet Res. 2012 Jun 22;14(3):e91</RefSource>                <PMID Version="1">22743581</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Psychiatry. 2014 Oct 18;14:290</RefSource>                <PMID Version="1">25326035</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes Care. 2015 May;38(5):776-83</RefSource>                <PMID Version="1">25710923</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Methods Psychiatr Res. 2014 Sep;23(3):289-303</RefSource>                <PMID Version="1">24687693</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Res Ther. 2011 Jan;49(1):18-24</RefSource>                <PMID Version="1">21047620</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World Psychiatry. 2014 Feb;13(1):4-11</RefSource>                <PMID Version="1">24497236</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Internet Res. 2012 Aug 02;14(4):e110</RefSource>                <PMID Version="1">22858538</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2006 Oct 28;333(7574):883</RefSource>                <PMID Version="1">16935946</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):291-7</RefSource>                <PMID Version="1">20528315</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2011 Mar;129(1-3):117-25</RefSource>                <PMID Version="1">20889214</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Psychiatry. 2011 Jun 30;11:107</RefSource>                <PMID Version="1">21718523</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JMIR Ment Health. 2016 Aug 17;3(3):e38</RefSource>                <PMID Version="1">27535468</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Psychiatry. 2014 Apr 11;14:109</RefSource>                <PMID Version="1">24725765</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Res Ther. 2009 Mar;47(3):175-80</RefSource>                <PMID Version="1">19230862</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Patient Educ Couns. 2007 Apr;66(1):29-36</RefSource>                <PMID Version="1">17188453</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diabetes Res Clin Pract. 2014 Jul;105(1):30-9</RefSource>                <PMID Version="1">24862240</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Psychiatry. 2014 Jan 31;14:25</RefSource>                <PMID Version="1">24485283</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eval Program Plann. 1979;2(3):197-207</RefSource>                <PMID Version="1">10245370</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Assess. 2003 Jun;15(2):193-7</RefSource>                <PMID Version="1">12847779</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2012;7(5):e36905</RefSource>                <PMID Version="1">22615841</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World Psychiatry. 2014 Oct;13(3):288-95</RefSource>                <PMID Version="1">25273302</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2006 Feb 18;332(7538):413-6</RefSource>                <PMID Version="1">16484270</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Rev Pharmacoecon Outcomes Res. 2012 Dec;12(6):745-64</RefSource>                <PMID Version="1">23252357</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Health Expect. 2009 Mar;12(1):45-59</RefSource>                <PMID Version="1">19250152</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Psychiatry. 2013 Nov 07;13:296</RefSource>                <PMID Version="1">24199672</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Psychiatry. 2014 Dec 14;14:355</RefSource>                <PMID Version="1">25496393</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2016 Oct;46(13):2679-93</RefSource>                <PMID Version="1">27649340</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Psychiatry. 2017 Jan 21;17(1):36</RefSource>                <PMID Version="1">28109247</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2015 Feb 25;10(2):e0118681</RefSource>                <PMID Version="1">25714962</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Health Serv Res. 2001 Dec;36(6 Pt 1):987-1007</RefSource>                <PMID Version="1">11775672</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Blended therapy</Keyword>            <Keyword MajorTopicYN="N">Depression</Keyword>            <Keyword MajorTopicYN="N">Internet-based self-help</Keyword>            <Keyword MajorTopicYN="N">Patient's experience</Keyword>            <Keyword MajorTopicYN="N">Routine care</Keyword>            <Keyword MajorTopicYN="N">Video-based psychotherapy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>08</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2017</Year>                <Month>12</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>01</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30135780</ArticleId>            <ArticleId IdType="doi">10.1016/j.invent.2018.01.003</ArticleId>            <ArticleId IdType="pii">S2214-7829(17)30089-1</ArticleId>            <ArticleId IdType="pmc">PMC6096318</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30107350</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1573-2517</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>241</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Dec</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of affective disorders</Title>                <ISOAbbreviation>J Affect Disord</ISOAbbreviation>            </Journal>            <ArticleTitle>Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting.</ArticleTitle>            <Pagination>                <MedlinePgn>103-109</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0165-0327(18)30740-7</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2018.07.073</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Ketamine is known to rapidly reduce depressive symptoms and suicidal ideation (SI) in patients with major depressive disorder (MDD), but evidence is limited for its acceptability and effectiveness in &quot;real-world&quot; settings. This case series examines serial ketamine infusions in reducing SI and depression scores in adults with MDD admitted to a tertiary care hospital.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Five inpatients with MDD and SI admitted to hospital in Toronto, Canada received six infusions of 0.5 mg/kg intravenous (IV) ketamine (n = 5) over approximately 12 days, in addition to treatment-as-usual. Suicide and depression rating scores (Scale for Suicidal Ideation, SSI; Montgomery-Åsberg Depression Rating Scale, MADRS) were obtained at baseline, on treatment days, on days 14 and 42 (primary endpoint).</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients experienced benefit with ketamine. SSI scores diminished by 84% from 14.0 ± 4.5 at baseline to 2.2 ± 2.5 at study endpoint. MADRS scores diminished by 47% from 42.2 ± 5.3 at baseline to 22.4 ± 8.0. Two patients withdrew from the study, one to initiate electroconvulsive therapy and one due to an adverse event (dissociative effects) during the ketamine infusion.</AbstractText>                <AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The major limitation of this study is the small sample size.</AbstractText>                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">These preliminary pilot data are promising with a greater than two-fold reduction in SI following ketamine infusions. They demonstrate that six serial ketamine infusions may be safe and feasible. These findings support the need for large scale randomized controlled trials to confirm the efficacy of serial ketamine for treatment of SI in &quot;real-world&quot; settings.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier B.V.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Sinyor</LastName>                    <ForeName>Mark</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada. Electronic address: mark.sinyor@sunnybrook.ca.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Williams</LastName>                    <ForeName>Marissa</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Athabasca University, Athabasca, Alberta, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Belo</LastName>                    <ForeName>Sue</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anesthesia, Sunnybrook Health Sciences Centre, Toronto, Canada; Departments of Anesthesia, Pharmacology, Medicine and Clinical Pharmacology, University of Toronto, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Orser</LastName>                    <ForeName>Beverley</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anesthesia, Sunnybrook Health Sciences Centre, Toronto, Canada; Canadian Academy of Health Sciences, Ottawa, Ontario, Canada; Department of Anesthesia, University of Toronto, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vincent</LastName>                    <ForeName>Margaret</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>The University of Limerick, Limerick, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mah</LastName>                    <ForeName>Linda</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Geriatric Psychiatry, University of Toronto, Toronto, Canada; Rotman Research Institute, Baycrest Centre for Geriatric Care, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zarate</LastName>                    <ForeName>Carlos</ForeName>                    <Initials>C</Initials>                    <Suffix>Jr</Suffix>                    <AffiliationInfo>                        <Affiliation>National Institute of Mental Health (NIMH), Bethesda, MD, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Castel</LastName>                    <ForeName>Saulo</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Levitt</LastName>                    <ForeName>Anthony J</ForeName>                    <Initials>AJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schaffer</LastName>                    <ForeName>Ayal</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>J Affect Disord</MedlineTA>            <NlmUniqueID>7906073</NlmUniqueID>            <ISSNLinking>0165-0327</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Inpatients</Keyword>            <Keyword MajorTopicYN="N">Ketamine</Keyword>            <Keyword MajorTopicYN="N">Major depressive disorder</Keyword>            <Keyword MajorTopicYN="N">Midazolam</Keyword>            <Keyword MajorTopicYN="N">Suicide</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30107350</ArticleId>            <ArticleId IdType="pii">S0165-0327(18)30740-7</ArticleId>            <ArticleId IdType="doi">10.1016/j.jad.2018.07.073</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30107190</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>04</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1873-507X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>195</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>15</Day>                    </PubDate>                </JournalIssue>                <Title>Physiology &amp; behavior</Title>                <ISOAbbreviation>Physiol. Behav.</ISOAbbreviation>            </Journal>            <ArticleTitle>Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice.</ArticleTitle>            <Pagination>                <MedlinePgn>151-157</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0031-9384(18)30636-X</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.physbeh.2018.08.002</ELocationID>            <Abstract>                <AbstractText>Depression is associated with significant functional disabilities. Application of new drugs which could enhance the effectiveness of antidepressants drug and reduce side effects of their long-term use seems necessary. Citicoline is used as an effective chemical agent for improving the symptoms of some neurodegenerative diseases. Therefore, in this survey, the application of citicoline as an adjuvant drug was evaluated in mice model of depression. A total of 180 adult NMRI male albino mice were used in this study. All groups were exposed to chronic unexpected mild stress (CUMS) followed by treatment with various doses of citalopram or/and citicoline or saline for 21 days. Sucrose preference (SP), open field (OF), and forced swimming test (FST) were applied to evaluate depression symptoms in the groups. The results indicated that only citicoline at the 5 mg/kg dose had shifted its status from being noneffective to become significantly effective in the co-administered group. The means of SP, OFT, and FST of the treatment groups were significantly different in favor of co-administered group compared with the other groups as well as the control group. Based on the results, it can be concluded that administration of citicoline, as an adjuvant drug, in combination with citalopram, enhanced the effectiveness of selective serotonin reuptake inhibitors (SSRI) drugs for depression treatment.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Roohi-Azizi</LastName>                    <ForeName>Mahtab</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neuroscience, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Department of Rehabilitation Basic Sciences, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Torkaman-Boutorabi</LastName>                    <ForeName>Anahita</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neuroscience, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Akhondzadeh</LastName>                    <ForeName>Shahin</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nejatisafa</LastName>                    <ForeName>Ali-Akbar</ForeName>                    <Initials>AA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Psychosomatic Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sadat-Shirazi</LastName>                    <ForeName>Mitra-Sadat</ForeName>                    <Initials>MS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neuroscience, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zarrindast</LastName>                    <ForeName>Mohammad-Reza</ForeName>                    <Initials>MR</Initials>                    <AffiliationInfo>                        <Affiliation>Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran.; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Department of Neuroendocrinology, Endocrinology and Metabolism Research Institute, Tehran University of Medical Science, Tehran, Iran. Electronic address: zarinmr@ams.ac.ir.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Physiol Behav</MedlineTA>            <NlmUniqueID>0151504</NlmUniqueID>            <ISSNLinking>0031-9384</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Citalopram</Keyword>            <Keyword MajorTopicYN="N">Citicoline</Keyword>            <Keyword MajorTopicYN="N">Co-administration</Keyword>            <Keyword MajorTopicYN="N">Forced swimming test</Keyword>            <Keyword MajorTopicYN="N">Open field test</Keyword>            <Keyword MajorTopicYN="N">Sucrose preference test</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30107190</ArticleId>            <ArticleId IdType="pii">S0031-9384(18)30636-X</ArticleId>            <ArticleId IdType="doi">10.1016/j.physbeh.2018.08.002</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30106471</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1469-493X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>8</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>14</Day>                    </PubDate>                </JournalIssue>                <Title>The Cochrane database of systematic reviews</Title>                <ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>            </Journal>            <ArticleTitle>Mindfulness-based stress reduction for family carers of people with dementia.</ArticleTitle>            <Pagination>                <MedlinePgn>CD012791</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD012791.pub2</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Caring for people with dementia is highly challenging, and family carers are recognised as being at increased risk of physical and mental ill-health. Most current interventions have limited success in reducing stress among carers of people with dementia. Mindfulness-based stress reduction (MBSR) draws on a range of practices and may be a promising approach to helping carers of people with dementia.</AbstractText>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the effectiveness of MBSR in reducing the stress of family carers of people with dementia.</AbstractText>                <AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">We searched ALOIS - the Cochrane Dementia and Cognitive Improvement Group's Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (all years to Issue 9 of 12, 2017), MEDLINE (Ovid SP 1950 to September 2017), Embase (Ovid SP 1974 to Sepetmber 2017), Web of Science (ISI Web of Science 1945 to September 2017), PsycINFO (Ovid SP 1806 to September 2017), CINAHL (all dates to September 2017), LILACS (all dates to September 2017), World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, and Dissertation Abstracts International (DAI) up to 6 September 2017, with no language restrictions.</AbstractText>                <AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised controlled trials (RCTs) of MBSR for family carers of people with dementia.</AbstractText>                <AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two review authors independently screened references for inclusion criteria, extracted data, assessed the risk of bias of trials with the Cochrane 'Risk of bias' tool, and evaluated the quality of the evidence using the GRADE instrument. We contacted study authors for additional information, then conducted meta-analyses, or reported results narratively in the case of insufficient data. We used standard methodological procedures expected by Cochrane.</AbstractText>                <AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">We included five RCTs involving 201 carers assessing the effectiveness of MBSR. Controls used in included studies varied in structure and content. Mindfulness-based stress reduction programmes were compared with either active controls (those matched for time and attention with MBSR, i.e. education, social support, or progressive muscle relaxation), or inactive controls (those not matched for time and attention with MBSR, i.e. self help education or respite care). One trial used both active and inactive comparisons with MBSR. All studies were at high risk of bias in terms of blinding of outcome assessment. Most studies provided no information about selective reporting, incomplete outcome data, or allocation concealment.1. Compared with active controls, MBSR may reduce depressive symptoms of carers at the end of the intervention (3 trials, 135 participants; standardised mean difference (SMD) -0.63, 95% confidence interval (CI) -0.98 to -0.28; P&lt;0.001; low-quality evidence). We could not be certain of any effect on clinically significant depressive symptoms (very low-quality evidence).Mindfulness-based stress reduction compared with active control may decrease carer anxiety at the end of the intervention (1 trial, 78 participants; mean difference (MD) -7.50, 95% CI -13.11 to -1.89; P&lt;0.001; low-quality evidence) and may slightly increase carer burden (3 trials, 135 participants; SMD 0.24, 95% CI -0.11 to 0.58; P=0.18; low-quality evidence), although both results were imprecise, and we could not exclude little or no effect. Due to the very low quality of the evidence, we could not be sure of any effect on carers' coping style, nor could we determine whether carers were more or less likely to drop out of treatment.2. Compared with inactive controls, MBSR showed no clear evidence of any effect on depressive symptoms (2 trials, 50 participants; MD -1.97, 95% CI -6.89 to 2.95; P=0.43; low-quality evidence). We could not be certain of any effect on clinically significant depressive symptoms (very low-quality evidence).In this comparison, MBSR may also reduce carer anxiety at the end of the intervention (1 trial, 33 participants; MD -7.27, 95% CI -14.92 to 0.38; P=0.06; low-quality evidence), although we were unable to exclude little or no effect. Due to the very low quality of the evidence, we could not be certain of any effects of MBSR on carer burden, the use of positive coping strategies, or dropout rates.We found no studies that looked at quality of life of carers or care-recipients, or institutionalisation.Only one included study reported on adverse events, noting a single adverse event related to yoga practices at home AUTHORS' CONCLUSIONS: After accounting for non-specific effects of the intervention (i.e. comparing it with an active control), low-quality evidence suggests that MBSR may reduce carers' depressive symptoms and anxiety, at least in the short term.There are significant limitations to the evidence base on MBSR in this population. Our GRADE assessment of the evidence was low to very low quality. We downgraded the quality of the evidence primarily because of high risk of detection or performance bias, and imprecision.In conclusion, MBSR has the potential to meet some important needs of the carer, but more high-quality studies in this field are needed to confirm its efficacy.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Zheng</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Maternal and Child Health, School of Public Health, Peking University, 38 Xueyuan Road, Beijing, China, 100191.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sun</LastName>                    <ForeName>Yu-Ying</ForeName>                    <Initials>YY</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Zhong</LastName>                    <ForeName>Bao-Liang</ForeName>                    <Initials>BL</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>14</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Cochrane Database Syst Rev</MedlineTA>            <NlmUniqueID>100909747</NlmUniqueID>            <ISSNLinking>1361-6137</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30106471</ArticleId>            <ArticleId IdType="doi">10.1002/14651858.CD012791.pub2</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30100641</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>15</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">0091-1674</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>46</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Clinical social work journal</Title>                <ISOAbbreviation>Clin Soc Work J</ISOAbbreviation>            </Journal>            <ArticleTitle>Remission from Depression in the DSM: Moving from Rhetoric to Restoration.</ArticleTitle>            <Pagination>                <MedlinePgn>220-227</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10615-017-0635-4</ELocationID>            <Abstract>                <AbstractText>The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders, uses the term &quot;remission&quot; to describe the reduction of depressive symptoms. This paper argues that by categorizing someone who no longer has depressive symptoms as &quot;in remission,&quot; that person may feel indefinitely tied to his or her diagnosis. Considering the unfortunate stigma associated with mental illness, permanent linkage to diagnosis through records and professional memory may cause individuals to internalize pathology. In fact, the language of the diagnosis can affect self-perception in sensitive souls for a lifetime. As an implication for practice, we propose that cognitive and narrative therapy approaches, mood-memoirs, and use of metaphor present alternative uses of language that can reduce power imbalances between clinicians and clients, providing a bridge to healing.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Gesicki</LastName>                    <ForeName>Paige</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Social Work, Department of Clinical Sciences, Brunel University London, Kingston Lane, UXBRIDGE, UB8 3PH UK.</Affiliation>                        <Identifier Source="ISNI">0000 0001 0724 6933</Identifier>                        <Identifier Source="GRID">grid.7728.a</Identifier>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nelson-Becker</LastName>                    <ForeName>Holly</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Social Work, Department of Clinical Sciences, Brunel University London, Kingston Lane, UXBRIDGE, UB8 3PH UK.</Affiliation>                        <Identifier Source="ISNI">0000 0001 0724 6933</Identifier>                        <Identifier Source="GRID">grid.7728.a</Identifier>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2017</Year>                <Month>06</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Clin Soc Work J</MedlineTA>            <NlmUniqueID>0365260</NlmUniqueID>            <ISSNLinking>0091-1674</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Rehabil Nurs. 2000 Sep-Oct;25(5):170-6</RefSource>                <PMID Version="1">11998082</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychother Res. 2011 Jan;21(1):4-15</RefSource>                <PMID Version="1">20306354</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychother Res. 2014;24(6):662-74</RefSource>                <PMID Version="1">24479576</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2012 Dec 15;142(1-3):77-81</RefSource>                <PMID Version="1">22980402</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 1991 Sep;48(9):851-5</RefSource>                <PMID Version="1">1929776</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychother Res. 2016 Jul;26(4):425-35</RefSource>                <PMID Version="1">25968420</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 2010 Nov;167(11):1305-20</RefSource>                <PMID Version="1">20843874</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 2006 Jan;163(1):148-50</RefSource>                <PMID Version="1">16390903</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychopharmacol. 2005 Aug;25(4 Suppl 1):S24-8</RefSource>                <PMID Version="1">16027557</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cochrane Database Syst Rev. 2013 Oct 16;(10):CD008696</RefSource>                <PMID Version="1">24129886</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2007 Sep;102(1-3):93-9</RefSource>                <PMID Version="1">17258323</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Adv Nurs. 1999 Feb;29(2):331-40</RefSource>                <PMID Version="1">10197932</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">DSM-5</Keyword>            <Keyword MajorTopicYN="N">Depression</Keyword>            <Keyword MajorTopicYN="N">Language</Keyword>            <Keyword MajorTopicYN="N">Metaphor</Keyword>            <Keyword MajorTopicYN="N">Mood memoirs</Keyword>            <Keyword MajorTopicYN="N">Narrative theory</Keyword>            <Keyword MajorTopicYN="N">Remission</Keyword>        </KeywordList>        <CoiStatement>Compliance with Ethical StandardsThe authors declare that they have no conflict of interest.This article does not contain any studies with human participants or animals performed by any of the authors.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30100641</ArticleId>            <ArticleId IdType="doi">10.1007/s10615-017-0635-4</ArticleId>            <ArticleId IdType="pii">635</ArticleId>            <ArticleId IdType="pmc">PMC6061124</ArticleId>        </ArticleIdList>        <?pmcsd?>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30094824</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>31</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-5415</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of the American Geriatrics Society</Title>                <ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation>            </Journal>            <ArticleTitle>Burden of Depressive Symptoms Over 2 Decades and Risk of Nursing Home Placement in Older Women.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jgs.15496</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the association between cumulative burden of depressive symptoms and risk of nursing home (NH) placement over 2 decades.</AbstractText>                <AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study with data linked to Medicare claims files.</AbstractText>                <AbstractText Label="SETTING" NlmCategory="METHODS">Clinic sites in Baltimore, Maryland; Minneapolis, Minnesota; and the Monongahela Valley near Pittsburgh, Pennsylvania.</AbstractText>                <AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Initially community-dwelling women aged 65 and older (N=3,646).</AbstractText>                <AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Depressive symptom burden was determined using the Geriatric Depression Scale measured over 18 years to calculate accumulation of burden. NH placement was determined using Medicare claims data.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In Fine-Gray proportional hazards analyses including demographic characteristics, medical comorbidities, functional impairment, and recent depression exposure and accounting for competing risk of death, women with low depressive symptom burden were twice as likely to experience NH placement as those with minimal burden (hazard ratio (HR) = 1.92, 95% confidence interval (CI) = 1.16-3.20), women with moderate burden were more than twice as likely (HR = 2.62, 95% CI = 1.59-4.31), and women with high burden (HR = 3.08, 95% CI = 1.87-5.08) were three times as likely. The addition of antidepressant use to this model attenuated the risk only slightly.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In older women, cumulative burden of depressive symptoms over nearly 2 decades is associated with greater risk of transitioning from community-living to a NH irrespective of recent depression exposure, medical comorbidities, functional impairment, and the competing risk of death. This work supports the need for improving recognition, monitoring, and treatment of depressive symptoms early, which may reduce or delay NH placement.</AbstractText>                <CopyrightInformation>© 2018, Copyright the Authors Journal compilation © 2018, The American Geriatrics Society.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Byers</LastName>                    <ForeName>Amy L</ForeName>                    <Initials>AL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, University of California, San Francisco, San Francisco, California.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>San Francisco Veterans Affairs Health Care System, San Francisco, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lui</LastName>                    <ForeName>Li-Yung</ForeName>                    <Initials>LY</Initials>                    <AffiliationInfo>                        <Affiliation>Research Institute, California Pacific Medical Center, San Francisco, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vittinghoff</LastName>                    <ForeName>Eric</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Covinsky</LastName>                    <ForeName>Kenneth E</ForeName>                    <Initials>KE</Initials>                    <AffiliationInfo>                        <Affiliation>San Francisco Veterans Affairs Health Care System, San Francisco, California.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Geriatrics, Department of Medicine, University of California, San Francisco, San Francisco, California.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ensrud</LastName>                    <ForeName>Kristine E</ForeName>                    <Initials>KE</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-9069-3036</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, University of Minnesota, Minneapolis, Minnesota.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Taylor</LastName>                    <ForeName>Brent</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, University of Minnesota, Minneapolis, Minnesota.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yaffe</LastName>                    <ForeName>Kristine</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, University of California, San Francisco, San Francisco, California.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>San Francisco Veterans Affairs Health Care System, San Francisco, California.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, California.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>R01 AR035583</GrantID>                    <Acronym>AR</Acronym>                    <Agency>NIAMS NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 AR035584</GrantID>                    <Acronym>AR</Acronym>                    <Agency>NIAMS NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 MD007019</GrantID>                    <Acronym>MD</Acronym>                    <Agency>NIMHD NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 MH086498</GrantID>                    <Acronym>MH</Acronym>                    <Agency>NIMH NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 AG027576</GrantID>                    <Acronym>AG</Acronym>                    <Agency>NIA NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>K24 AG031155</GrantID>                    <Acronym>AG</Acronym>                    <Agency>NIA NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 AG005407</GrantID>                    <Acronym>AG</Acronym>                    <Agency>NIA NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 AR035582</GrantID>                    <Acronym>AR</Acronym>                    <Agency>NIAMS NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 AG005394</GrantID>                    <Acronym>AG</Acronym>                    <Agency>NIA NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 AG027574</GrantID>                    <Acronym>AG</Acronym>                    <Agency>NIA NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Am Geriatr Soc</MedlineTA>            <NlmUniqueID>7503062</NlmUniqueID>            <ISSNLinking>0002-8614</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">aging</Keyword>            <Keyword MajorTopicYN="N">care transitions</Keyword>            <Keyword MajorTopicYN="N">depression</Keyword>            <Keyword MajorTopicYN="N">epidemiology</Keyword>            <Keyword MajorTopicYN="N">institutionalization</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>04</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>05</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30094824</ArticleId>            <ArticleId IdType="doi">10.1111/jgs.15496</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30089966</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">0972-6748</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>26</Volume>                    <Issue>2</Issue>                    <PubDate>                        <MedlineDate>2017 Jul-Dec</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>Industrial psychiatry journal</Title>                <ISOAbbreviation>Ind Psychiatry J</ISOAbbreviation>            </Journal>            <ArticleTitle>Neuropsychological deficits in elderly with depression.</ArticleTitle>            <Pagination>                <MedlinePgn>178-182</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4103/ipj.ipj_86_14</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Depressed patients are preoccupied with unhappy thoughts which reduce their capacity to focus on attention, memory, and other cognitive performance.</AbstractText>                <AbstractText Label="Aim" NlmCategory="UNASSIGNED">The aim of this study is to assess neuropsychological deficits in elderly depressive and compare it with matched normal controls.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">After consideration of inclusion and exclusion criteria, the sample of 30 elderly depressive patients diagnosed on the basis of International Classification of Diseases, Tenth Edition criteria and 30 normal controls were selected. The selection of sample was by purposive sampling from private psychiatric clinic of Bhopal. The age range of sample was 60 years and above. All participants were administered the Geriatric Depression Scale, and the Luria-Nebraska Neuropsychological Battery-1 (LNNB form-1).</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">On the Geriatric Depression Scale, 21 patients were at mild level and nine patients were at severe level of depression. None of the normal controls were depressed. On LNNB form-1, depressive patients showed significant elevation on receptive speech, arithmetic, memory, reading, writing, and expressive speech as compared to normal controls.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Older depressive patients showed significantly more neurocognitive deficits as compared to normal controls. It is important that these deficits are identified and addressed for the holistic treatment of late-onset depression.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ranjan</LastName>                    <ForeName>Rupesh</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, BMHRC, Bhopal, Madhya Pradesh, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Priyamvada</LastName>                    <ForeName>Richa</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, Patna University, Patna, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jha</LastName>                    <ForeName>Gyanendra Kumar</ForeName>                    <Initials>GK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, People's Medical College, Bhanpur, Bhopal, Madhya Pradesh, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chaudhury</LastName>                    <ForeName>Suprakash</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Dr D Y Patil Medical College, Pimpri, Pune, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>India</Country>            <MedlineTA>Ind Psychiatry J</MedlineTA>            <NlmUniqueID>101547239</NlmUniqueID>            <ISSNLinking>0972-6748</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3908-13</RefSource>                <PMID Version="1">8632988</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2010 Apr;40(4):591-602</RefSource>                <PMID Version="1">19656429</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 1995 Jun 8;34(3):227-34</RefSource>                <PMID Version="1">7560551</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Dement Geriatr Cogn Disord. 2006;21(2):104-12</RefSource>                <PMID Version="1">16374005</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuron. 2005 Mar 3;45(5):651-60</RefSource>                <PMID Version="1">15748841</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Geriatr Psychiatry. 2005 Jun;20(6):576-86</RefSource>                <PMID Version="1">15920709</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Gerontol A Biol Sci Med Sci. 2003 May;58(5):M461-7</RefSource>                <PMID Version="1">12730257</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurologist. 2007 May;13(3):105-17</RefSource>                <PMID Version="1">17495754</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cogn Neurosci. 2002 Nov 15;14(8):1215-29</RefSource>                <PMID Version="1">12495527</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 1993 Dec;29(4):243-53</RefSource>                <PMID Version="1">8126311</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychiatry Res. 1999 Dec 27;89(3):171-87</RefSource>                <PMID Version="1">10708264</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World Psychiatry. 2004 Feb;3(1):45-9</RefSource>                <PMID Version="1">16633454</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 1995 Oct 9;35(1-2):1-9</RefSource>                <PMID Version="1">8557882</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Abnorm Psychol. 1992 Aug;101(3):575-80</RefSource>                <PMID Version="1">1500616</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):98-106</RefSource>                <PMID Version="1">11790640</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 1994 Sep 15;36(6):381-8</RefSource>                <PMID Version="1">7803599</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):162-71</RefSource>                <PMID Version="1">10071094</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Indian J Physiol Pharmacol. 2007 Jan-Mar;51(1):69-75</RefSource>                <PMID Version="1">17877295</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 1992 Sep;12(9):3628-41</RefSource>                <PMID Version="1">1527602</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 1998 Apr;39(4):608-12</RefSource>                <PMID Version="1">9544664</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 2004 Jun;61(6):587-95</RefSource>                <PMID Version="1">15184238</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Psychiatry. 2001 Mar;178:200-6</RefSource>                <PMID Version="1">11230029</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 1989 Mar;46(3):243-50</RefSource>                <PMID Version="1">2784046</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 1997 Apr;154(4):497-501</RefSource>                <PMID Version="1">9090336</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cereb Cortex. 2000 Mar;10(3):206-19</RefSource>                <PMID Version="1">10731217</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Encephale. 2009 Sep;35(4):361-9</RefSource>                <PMID Version="1">19748373</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Age Ageing. 2005 May;34(3):242-8</RefSource>                <PMID Version="1">15863409</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Exp Psychol Gen. 1990 Mar;119(1):45-59</RefSource>                <PMID Version="1">2141063</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 1999 Jan;29(1):73-85</RefSource>                <PMID Version="1">10077295</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychiatr Res. 1982-1983;17(1):37-49</RefSource>                <PMID Version="1">7183759</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychopharmacol. 1997;11(2):115-22</RefSource>                <PMID Version="1">9208375</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychiatr Dis Treat. 2009;5:517-26</RefSource>                <PMID Version="1">19851519</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Geriatric depression</Keyword>            <Keyword MajorTopicYN="N">Luria Nebraska Neuropsychological Battery form-1</Keyword>            <Keyword MajorTopicYN="N">neuropsychological deficits</Keyword>        </KeywordList>        <CoiStatement>There are no conflicts of interest.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30089966</ArticleId>            <ArticleId IdType="doi">10.4103/ipj.ipj_86_14</ArticleId>            <ArticleId IdType="pii">IPJ-26-178</ArticleId>            <ArticleId IdType="pmc">PMC6058441</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30088131</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>23</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1573-6601</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>07</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of youth and adolescence</Title>                <ISOAbbreviation>J Youth Adolesc</ISOAbbreviation>            </Journal>            <ArticleTitle>Immunocognitive Model of Depression Secondary to Anxiety in Adolescents.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10964-018-0905-7</ELocationID>            <Abstract>                <AbstractText>There is evidence that anxiety precedes the onset of depression and that rumination contributes to this risk pathway in adolescence. This study examined inflammatory biomarkers as mediators in a risk model of depressive symptoms secondary to anxiety symptoms among adolescents who ruminate. A sample of 140 adolescents (52% female, 54% African American, 40% Caucasian, 6% biracial, mean age at T1 = 16.5 years, SD = 1.2 years) provided blood samples on two visits (T1 and T2; mean time between T1 and T2 = 13.5 months, SD = 5.9 months). Self-report anxiety, depression, and rumination measures were given at T1 and the depression measure was given again at a third visit (T3, mean months since T1 = 26.0 months, SD = 9.0 months). Higher anxiety predicted more interleukin-6, but not more C-reactive protein, for adolescents with high levels of rumination. Moderated mediation analyses (N for analysis after removing cases with missing data and outliers = 86) indicated that interleukin-6, but not C-reactive protein, at T2 mediated the relationship between anxiety symptoms at T1 and depressive symptoms at T3, conditional on rumination. Anxiety and rumination interacted such that, as rumination increased, anxiety predicted greater inflammation and depressive symptoms. These results demonstrate that established cognitive vulnerabilities for the development of depressive symptoms secondary to anxiety symptoms in adolescence might indirectly operate though biological mechanisms such as inflammation. In addition to highlighting risk factors and potential treatment targets for depression, this study suggests a potential biological mechanism underlying the effects of psychotherapies that reduce rumination on negative affect (e.g., cognitive behavioral therapy).</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Moriarity</LastName>                    <ForeName>Daniel P</ForeName>                    <Initials>DP</Initials>                    <AffiliationInfo>                        <Affiliation>Temple University, Philadelphia, PA, 19122, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McArthur</LastName>                    <ForeName>Brae Anne</ForeName>                    <Initials>BA</Initials>                    <AffiliationInfo>                        <Affiliation>Temple University, Philadelphia, PA, 19122, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ellman</LastName>                    <ForeName>Lauren M</ForeName>                    <Initials>LM</Initials>                    <AffiliationInfo>                        <Affiliation>Temple University, Philadelphia, PA, 19122, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Coe</LastName>                    <ForeName>Christopher L</ForeName>                    <Initials>CL</Initials>                    <AffiliationInfo>                        <Affiliation>University of Wisconsin-Madison, Madison, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Abramson</LastName>                    <ForeName>Lyn Y</ForeName>                    <Initials>LY</Initials>                    <AffiliationInfo>                        <Affiliation>University of Wisconsin-Madison, Madison, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Alloy</LastName>                    <ForeName>Lauren B</ForeName>                    <Initials>LB</Initials>                    <AffiliationInfo>                        <Affiliation>Temple University, Philadelphia, PA, 19122, USA. lalloy@temple.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>R01 MH101168</GrantID>                    <Acronym>MH</Acronym>                    <Agency>NIMH NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>MH101168</GrantID>                    <Agency>National Institute of Mental Health</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Youth Adolesc</MedlineTA>            <NlmUniqueID>0333507</NlmUniqueID>            <ISSNLinking>0047-2891</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Anxiety</Keyword>            <Keyword MajorTopicYN="N">Comorbidity</Keyword>            <Keyword MajorTopicYN="N">Depression</Keyword>            <Keyword MajorTopicYN="N">Inflammation</Keyword>            <Keyword MajorTopicYN="N">Rumination</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30088131</ArticleId>            <ArticleId IdType="doi">10.1007/s10964-018-0905-7</ArticleId>            <ArticleId IdType="pii">10.1007/s10964-018-0905-7</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30077114</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>20</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-1379</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>104</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of psychiatric research</Title>                <ISOAbbreviation>J Psychiatr Res</ISOAbbreviation>            </Journal>            <ArticleTitle>Ketamine in electroconvulsive therapy for depressive disorder: A systematic review and meta-analysis.</ArticleTitle>            <Pagination>                <MedlinePgn>144-156</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0022-3956(18)30211-5</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2018.07.003</ELocationID>            <Abstract>                <AbstractText>Electroconvulsive therapy (ECT) is one of the most effective treatments for depressive disorder. Sub-anesthetic dose of ketamine exerts a rapid and robust antidepressive effect. However, it is still unclear whether ketamine usage in ECT is efficacious as an antidepressant. We aimed to conduct a systematic review and meta-analysis on the effects of ketamine in ECT among patients with depressive disorder. MEDLINE, EMBASE, the CENTRAL and PsycINFO for randomized controlled trials were searched to assess the effects of ketamine used in ECT until 31 Mar 2018 (PROSPERO: CRD42018081024). Sixteen studies including 928 patients were enrolled. At the end of ECT, no significant standardized mean difference (SMD) was observed in favor of the ketamine group. Depressive scores were lower in the ketamine group after 1st ECT and 3rd to 6th ECTs. The depressive scores were lower after 2nd, 3rd, 4th and 6th ECTs when the ketamine was used as an add-on anesthetic, while the depressive scores were lower after 1st ECT when ketamine alone was used. Ketamine in ECT showed no better response and remission rate, while increased adverse events, especially related to cardiovascular and psychiatric systems, during the whole ECT course. In conclusion, although ketamine used in ECT cannot reduce the depressive symptoms at the end of treatment, it could accelerate the antidepressive effect in depressive patients receiving ECT, especially in those who used ketamine as an add-on anesthetic. However, ketamine cautiously needs to be administered in ECT due to the possibility of increased risk of side effects.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ren</LastName>                    <ForeName>Li</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anesthesiology, The First Affiliated Hospital of Chongqing Medical University, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Deng</LastName>                    <ForeName>Jie</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anesthesiology, The First Affiliated Hospital of Chongqing Medical University, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Min</LastName>                    <ForeName>Su</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anesthesiology, The First Affiliated Hospital of Chongqing Medical University, China. Electronic address: ms89011068@163.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Peng</LastName>                    <ForeName>Lihua</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anesthesiology, The First Affiliated Hospital of Chongqing Medical University, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Qibin</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anesthesiology, The First Affiliated Hospital of Chongqing Medical University, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Psychiatr Res</MedlineTA>            <NlmUniqueID>0376331</NlmUniqueID>            <ISSNLinking>0022-3956</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Depression</Keyword>            <Keyword MajorTopicYN="N">Electroconvulsive therapy</Keyword>            <Keyword MajorTopicYN="N">Ketamine</Keyword>            <Keyword MajorTopicYN="N">Meta-analysis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30077114</ArticleId>            <ArticleId IdType="pii">S0022-3956(18)30211-5</ArticleId>            <ArticleId IdType="doi">10.1016/j.jpsychires.2018.07.003</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30076546</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>04</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1432-0711</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>03</Day>                    </PubDate>                </JournalIssue>                <Title>Archives of gynecology and obstetrics</Title>                <ISOAbbreviation>Arch. Gynecol. Obstet.</ISOAbbreviation>            </Journal>            <ArticleTitle>Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00404-018-4864-8</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Endometriosis is a debilitating disease with high recurrence rates requiring long-term management. Progestins such as dienogest are used empirically when first symptoms occur and post-surgery to reduce recurrence. This retrospective, practice-based study assessed the efficacy and safety of dienogest in women with endometriosis treated for at least 60 months.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">37 women (age 39 ± 8 years) with laparoscopically diagnosed endometriosis received dienogest 2 mg orally once daily. Endometriosis-associated pelvic pain (EAPP) was measured on a 0-100 mm visual analog scale at baseline and every 12 months. Laboratory measures of lipid and liver metabolism, hemostatic and hormonal parameters were investigated in a subgroup of 15 women. Adverse events including bleeding disturbances and depressive symptoms were recorded.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In 22 women, dienogest was begun after laparoscopy; median EAPP score was 70 mm pre-surgery and 10, 10, 20, 20, and 20 mm, respectively, after 12, 24, 36, 48, and 60 months of dienogest treatment. Another 15 women began dienogest without prior surgery; median EAPP score was 80 mm pretreatment and 20, 20, 30, 30, and 30 mm, respectively, after 12, 24, 36, 48, and 60 months. All laboratory parameters remained within the normal range. Mean serum estradiol was 28 ± 12 pg/ml after 60 months. Seven women experienced spotting episodes and four women presented with phases of depressed mood, which could all be clinically managed.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long-term (60-month) treatment with dienogest 2 mg once-daily in women with endometriosis effectively reduced EAPP and avoided pain recurrence post-surgery. Dienogest was well tolerated and adverse effects were clinically managed.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Römer</LastName>                    <ForeName>Thomas</ForeName>                    <Initials>T</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5241-8095</Identifier>                    <AffiliationInfo>                        <Affiliation>Obstetrics and Gynecology Department, Academic Hospital Weyertal, University of Cologne, 50931, Cologne, Germany. roemerth62@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Arch Gynecol Obstet</MedlineTA>            <NlmUniqueID>8710213</NlmUniqueID>            <ISSNLinking>0932-0067</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Dienogest</Keyword>            <Keyword MajorTopicYN="N">Endometriosis</Keyword>            <Keyword MajorTopicYN="N">Long-term management</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30076546</ArticleId>            <ArticleId IdType="doi">10.1007/s00404-018-4864-8</ArticleId>            <ArticleId IdType="pii">10.1007/s00404-018-4864-8</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>